metformin has been researched along with Pre-Eclampsia in 40 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Pre-Eclampsia: A complication of PREGNANCY, characterized by a complex of symptoms including maternal HYPERTENSION and PROTEINURIA with or without pathological EDEMA. Symptoms may range between mild and severe. Pre-eclampsia usually occurs after the 20th week of gestation, but may develop before this time in the presence of trophoblastic disease.
| Excerpt | Relevance | Reference |
|---|---|---|
| " However, the contribution of PROK1 to the development of pregnancy complications and the effect of metformin and hyperandrogenism on s-PROK1 in PCOS have not been studied previously." | 9.69 | Maternal serum levels of prokineticin-1 related to pregnancy complications and metformin use in women with polycystic ovary syndrome: a post hoc analysis of two prospective, randomised, placebo-controlled trials. ( Hirschberg, AL; Trouva, A; Ujvari, D; Vanky, E, 2023) |
| "This trial suggests that extended release metformin can prolong gestation in women with preterm pre-eclampsia, although further trials are needed." | 9.41 | Use of metformin to prolong gestation in preterm pre-eclampsia: randomised, double blind, placebo controlled trial. ( Brownfoot, F; Cluver, CA; Decloedt, EH; Hall, DR; Hiscock, R; Kaitu'u-Lino, TJ; Mol, BW; Schell, S; Tong, S; Walker, SP, 2021) |
| "Less maternal weight gain was found in the metformin treated groups (9." | 9.20 | Metformin versus insulin treatment in gestational diabetes in pregnancy in a developing country: a randomized control trial. ( Ainuddin, J; Hasan, AA; Karim, N; Naqvi, SA, 2015) |
| "In 76 PCOS women, first pregnancy miscarriage and live birth were compared before and on metformin/diet, started 6." | 9.17 | Effects of metformin-diet intervention before and throughout pregnancy on obstetric and neonatal outcomes in patients with polycystic ovary syndrome. ( Glueck, CJ; Goldenberg, N; Khan, Z; Padda, J; Pranikoff, J; Wang, P, 2013) |
| "Metformin treatment from first trimester to delivery did not reduce pregnancy complications in PCOS." | 9.14 | Metformin versus placebo from first trimester to delivery in polycystic ovary syndrome: a randomized, controlled multicenter study. ( Almås, I; Berg, AH; Berg, KF; Bjerke, C; Bunford, G; Carlsen, SM; Danielson, A; Eikeland, T; Flo, K; Heimstad, R; Hjelle, S; Kleggetveit, O; Lahmami, G; Lund, A; Romundstad, P; Skogøy, K; Stridsklev, S; Vanky, E; von Brandis, P, 2010) |
| "We prospectively assessed growth and motor-social development during the first 18 months of life in 126 live births (122 pregnancies) to 109 women with polycystic ovary syndrome (PCOS) who conceived on and continued metformin (1." | 9.11 | Height, weight, and motor-social development during the first 18 months of life in 126 infants born to 109 mothers with polycystic ovary syndrome who conceived on and continued metformin through pregnancy. ( Glueck, CJ; Goldenberg, N; Loftspring, M; Pranikoff, J; Sieve, L; Wang, P, 2004) |
| "To perform meta-analyses of studies evaluating the risk of pre-eclampsia in high-risk insulin-resistant women taking metformin prior to, or during pregnancy." | 8.98 | Risk of pre-eclampsia in women taking metformin: a systematic review and meta-analysis. ( Alqudah, A; Graham, U; Lyons, TJ; McClements, L; McKinley, MC; McNally, R; Watson, CJ, 2018) |
| " Only randomized controlled trials on metformin use, reporting the incidence of pre-eclampsia or pregnancy-induced hypertension, were included." | 8.98 | Metformin for prevention of hypertensive disorders of pregnancy in women with gestational diabetes or obesity: systematic review and meta-analysis of randomized trials. ( Abdi, A; Kalafat, E; Khalil, A; Sukur, YE; Thilaganathan, B, 2018) |
| "Our results showed that continued use during of metformin, during pregnancy in women with PCOS, had no effect on incidence of fetal abnormalities or fetal birth weight." | 8.93 | Effect of metformin treatment during pregnancy on women with PCOS: a systematic review and meta-analysis. ( Chang, Y; Fang, C; Li, S; Liu, H; Tan, X; Wang, Y; Zhang, X, 2016) |
| "To evaluate the efficacy of metformin administration throughout pregnancy on pregnancy-related complications in women with polycystic ovary syndrome (PCOS)." | 8.91 | Efficacy of metformin on pregnancy complications in women with polycystic ovary syndrome: a meta-analysis. ( Du, YK; Feng, L; Hu, D; Lin, XF; Wan, ZH, 2015) |
| " Metformin (MET) is an oral hypoglycemic agent that activates AMPK-regulated signaling pathways and inhibits inflammation and oxidative stress responses." | 8.31 | Protective role of metformin in preeclampsia via the regulation of NF-κB/sFlt-1 and Nrf2/HO-1 signaling pathways by activating AMPK. ( He, L; Li, X; Wu, J; Wu, X; Zhan, F, 2023) |
| " Metformin appears to reduce these risks in mothers with polycystic ovary syndrome and their children; but may increase the risk of childhood-obesity in children form women without PCOS." | 8.12 | Pregnancy, perinatal and childhood outcomes in women with and without polycystic ovary syndrome and metformin during pregnancy: a nationwide population-based study. ( Brusselaers, N; Crisosto, N; Cruz, G; Engstrand, L; Fornes, R; Nguyen, MH; Simin, J; van der Schaaf, M, 2022) |
| "Metformin exposure was associated with a decreased risk of composite hypertensive disorders of pregnancy in patients with pregestational type 2 diabetes." | 8.02 | Metformin Exposure and Risk of Hypertensive Disorders of Pregnancy in Patients with Type 2 Diabetes. ( Adams, JH; Antony, KM; Eddy, A; Hoppe, KK; Iruretagoyena, JI; Racine, JL; Rhoades, JS; Stewart, KS, 2021) |
| "Metformin has been reported to decrease insulin resistance and is associated with a lower risk of pregnancy-induced hypertension and preeclampsia." | 7.91 | Effect of Metformin on a Preeclampsia-Like Mouse Model Induced by High-Fat Diet. ( Cao, G; Cao, X; Li, L; Wang, F; Yi, W, 2019) |
| "Metformin has been reported to be involved in the pathogenesis of PE (pre-eclampsia)." | 7.91 | Treatment with metformin prevents pre-eclampsia by suppressing migration of trophoblast cells via modulating the signaling pathway of UCA1/miR-204/MMP-9. ( Ding, Y; Gu, W; Lu, L; Yuan, X, 2019) |
| "Metformin is a promising medication for the prevention or reduction of the incidence of GDM and pre-eclampsia in PCOS women." | 7.77 | Can metformin reduce the incidence of gestational diabetes mellitus in pregnant women with polycystic ovary syndrome? Prospective cohort study. ( Aboul Foutouh, I; Ashmawi, HS; Khattab, S; Mohsen, IA; Mohsen, MN; van der Veen, F; van Wely, M; Youssef, MA, 2011) |
| "Pregnant women with Type 2 DM who were treated with metformin had more risk factors for adverse pregnancy outcomes, but no differences in outcomes were seen compared with women not taking metformin." | 7.73 | Pregnancy in women with Type 2 diabetes: who takes metformin and what is the outcome? ( Hughes, RC; Rowan, JA, 2006) |
| "Metformin is not associated with pre-eclampsia in pregnancy in women with PCOS, and appears to be safe for mother and fetus." | 7.72 | Metformin, pre-eclampsia, and pregnancy outcomes in women with polycystic ovary syndrome. ( Bornovali, S; Dharashivkar, S; Glueck, CJ; Goldenberg, N; Pranikoff, J; Wang, P, 2004) |
| "Metformin has a molecular weight of 129 Daltons and therefore readily crosses the placenta." | 6.55 | Metformin, the aspirin of the 21st century: its role in gestational diabetes mellitus, prevention of preeclampsia and cancer, and the promotion of longevity. ( Conde-Agudelo, A; Erez, O; Grossman, LI; Hüttemann, M; Maymon, E; Pacora, P; Panaitescu, B; Romero, R; Yoon, BH, 2017) |
| " However, the contribution of PROK1 to the development of pregnancy complications and the effect of metformin and hyperandrogenism on s-PROK1 in PCOS have not been studied previously." | 5.69 | Maternal serum levels of prokineticin-1 related to pregnancy complications and metformin use in women with polycystic ovary syndrome: a post hoc analysis of two prospective, randomised, placebo-controlled trials. ( Hirschberg, AL; Trouva, A; Ujvari, D; Vanky, E, 2023) |
| "Metformin (Met) has been found to modify the methylation of H19 and to alter its expression." | 5.51 | Metformin exhibits its therapeutic effect in the treatment of pre-eclampsia via modulating the Met/H19/miR-148a-5p/P28 and Met/H19/miR-216-3p/EBI3 signaling pathways. ( Chen, C; Dong, S; Gu, J; He, J; Mo, Y; Shah, NK; Shu, C; Wu, L; Yan, D, 2019) |
| "Metformin has potential to prevent or treat preeclampsia." | 5.43 | Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction. ( Brownfoot, FC; Cannon, P; Hannan, NJ; Hastie, R; Illanes, SE; Kaitu'u-Lino, TJ; Parry, LJ; Senadheera, S; Tong, S; Tuohey, L, 2016) |
| "This trial suggests that extended release metformin can prolong gestation in women with preterm pre-eclampsia, although further trials are needed." | 5.41 | Use of metformin to prolong gestation in preterm pre-eclampsia: randomised, double blind, placebo controlled trial. ( Brownfoot, F; Cluver, CA; Decloedt, EH; Hall, DR; Hiscock, R; Kaitu'u-Lino, TJ; Mol, BW; Schell, S; Tong, S; Walker, SP, 2021) |
| "Less maternal weight gain was found in the metformin treated groups (9." | 5.20 | Metformin versus insulin treatment in gestational diabetes in pregnancy in a developing country: a randomized control trial. ( Ainuddin, J; Hasan, AA; Karim, N; Naqvi, SA, 2015) |
| "In 76 PCOS women, first pregnancy miscarriage and live birth were compared before and on metformin/diet, started 6." | 5.17 | Effects of metformin-diet intervention before and throughout pregnancy on obstetric and neonatal outcomes in patients with polycystic ovary syndrome. ( Glueck, CJ; Goldenberg, N; Khan, Z; Padda, J; Pranikoff, J; Wang, P, 2013) |
| "Metformin treatment from first trimester to delivery did not reduce pregnancy complications in PCOS." | 5.14 | Metformin versus placebo from first trimester to delivery in polycystic ovary syndrome: a randomized, controlled multicenter study. ( Almås, I; Berg, AH; Berg, KF; Bjerke, C; Bunford, G; Carlsen, SM; Danielson, A; Eikeland, T; Flo, K; Heimstad, R; Hjelle, S; Kleggetveit, O; Lahmami, G; Lund, A; Romundstad, P; Skogøy, K; Stridsklev, S; Vanky, E; von Brandis, P, 2010) |
| "We prospectively assessed growth and motor-social development during the first 18 months of life in 126 live births (122 pregnancies) to 109 women with polycystic ovary syndrome (PCOS) who conceived on and continued metformin (1." | 5.11 | Height, weight, and motor-social development during the first 18 months of life in 126 infants born to 109 mothers with polycystic ovary syndrome who conceived on and continued metformin through pregnancy. ( Glueck, CJ; Goldenberg, N; Loftspring, M; Pranikoff, J; Sieve, L; Wang, P, 2004) |
| " Only randomized controlled trials on metformin use, reporting the incidence of pre-eclampsia or pregnancy-induced hypertension, were included." | 4.98 | Metformin for prevention of hypertensive disorders of pregnancy in women with gestational diabetes or obesity: systematic review and meta-analysis of randomized trials. ( Abdi, A; Kalafat, E; Khalil, A; Sukur, YE; Thilaganathan, B, 2018) |
| "To perform meta-analyses of studies evaluating the risk of pre-eclampsia in high-risk insulin-resistant women taking metformin prior to, or during pregnancy." | 4.98 | Risk of pre-eclampsia in women taking metformin: a systematic review and meta-analysis. ( Alqudah, A; Graham, U; Lyons, TJ; McClements, L; McKinley, MC; McNally, R; Watson, CJ, 2018) |
| "Our results showed that continued use during of metformin, during pregnancy in women with PCOS, had no effect on incidence of fetal abnormalities or fetal birth weight." | 4.93 | Effect of metformin treatment during pregnancy on women with PCOS: a systematic review and meta-analysis. ( Chang, Y; Fang, C; Li, S; Liu, H; Tan, X; Wang, Y; Zhang, X, 2016) |
| "26); whereas, significantly reduced results were found in the metformin group in pregnancy-induced hypertension (PIH) rate (RR = 0." | 4.91 | Effect comparison of metformin with insulin treatment for gestational diabetes: a meta-analysis based on RCTs. ( Cui, S; Li, G; Li, L; Li, Y; Xu, Y; Zhao, S, 2015) |
| "To evaluate the efficacy of metformin administration throughout pregnancy on pregnancy-related complications in women with polycystic ovary syndrome (PCOS)." | 4.91 | Efficacy of metformin on pregnancy complications in women with polycystic ovary syndrome: a meta-analysis. ( Du, YK; Feng, L; Hu, D; Lin, XF; Wan, ZH, 2015) |
| " Metformin (MET) is an oral hypoglycemic agent that activates AMPK-regulated signaling pathways and inhibits inflammation and oxidative stress responses." | 4.31 | Protective role of metformin in preeclampsia via the regulation of NF-κB/sFlt-1 and Nrf2/HO-1 signaling pathways by activating AMPK. ( He, L; Li, X; Wu, J; Wu, X; Zhan, F, 2023) |
| " Metformin appears to reduce these risks in mothers with polycystic ovary syndrome and their children; but may increase the risk of childhood-obesity in children form women without PCOS." | 4.12 | Pregnancy, perinatal and childhood outcomes in women with and without polycystic ovary syndrome and metformin during pregnancy: a nationwide population-based study. ( Brusselaers, N; Crisosto, N; Cruz, G; Engstrand, L; Fornes, R; Nguyen, MH; Simin, J; van der Schaaf, M, 2022) |
| "Metformin exposure was associated with a decreased risk of composite hypertensive disorders of pregnancy in patients with pregestational type 2 diabetes." | 4.02 | Metformin Exposure and Risk of Hypertensive Disorders of Pregnancy in Patients with Type 2 Diabetes. ( Adams, JH; Antony, KM; Eddy, A; Hoppe, KK; Iruretagoyena, JI; Racine, JL; Rhoades, JS; Stewart, KS, 2021) |
| "Recent evidence suggests that metformin may prevent pre-eclampsia by reverting the angiogenic imbalance in maternal sera." | 3.96 | Therapeutic doses of metformin do not have impact on angiogenesis in presence of sera from pre-eclamptic, IUGR and healthy pregnancies. ( Heinonen, T; Huttala, O; Laivuori, H; Tihtonen, K; Toimela, T; Uotila, J; Virtanen, A, 2020) |
| "Metformin has been reported to decrease insulin resistance and is associated with a lower risk of pregnancy-induced hypertension and preeclampsia." | 3.91 | Effect of Metformin on a Preeclampsia-Like Mouse Model Induced by High-Fat Diet. ( Cao, G; Cao, X; Li, L; Wang, F; Yi, W, 2019) |
| "Metformin has been reported to be involved in the pathogenesis of PE (pre-eclampsia)." | 3.91 | Treatment with metformin prevents pre-eclampsia by suppressing migration of trophoblast cells via modulating the signaling pathway of UCA1/miR-204/MMP-9. ( Ding, Y; Gu, W; Lu, L; Yuan, X, 2019) |
| " Glucose-induced inflammation was partially reversed by metformin." | 3.81 | Glucose and metformin modulate human first trimester trophoblast function: a model and potential therapy for diabetes-associated uteroplacental insufficiency. ( Abrahams, VM; Flannery, CA; Han, CS; Herrin, MA; Mulla, MJ; Pettker, CM; Pitruzzello, MC; Werner, EF, 2015) |
| "Metformin is a promising medication for the prevention or reduction of the incidence of GDM and pre-eclampsia in PCOS women." | 3.77 | Can metformin reduce the incidence of gestational diabetes mellitus in pregnant women with polycystic ovary syndrome? Prospective cohort study. ( Aboul Foutouh, I; Ashmawi, HS; Khattab, S; Mohsen, IA; Mohsen, MN; van der Veen, F; van Wely, M; Youssef, MA, 2011) |
| "Pregnant women with Type 2 DM who were treated with metformin had more risk factors for adverse pregnancy outcomes, but no differences in outcomes were seen compared with women not taking metformin." | 3.73 | Pregnancy in women with Type 2 diabetes: who takes metformin and what is the outcome? ( Hughes, RC; Rowan, JA, 2006) |
| "Metformin is not associated with pre-eclampsia in pregnancy in women with PCOS, and appears to be safe for mother and fetus." | 3.72 | Metformin, pre-eclampsia, and pregnancy outcomes in women with polycystic ovary syndrome. ( Bornovali, S; Dharashivkar, S; Glueck, CJ; Goldenberg, N; Pranikoff, J; Wang, P, 2004) |
| "A cohort study including all consecutively registered, orally treated pregnant diabetic patients set in a diabetic obstetrical service at a university hospital: 50 women treated with metformin, 68 women treated with sulphonylurea during pregnancy and a reference group of 42 diabetic women treated with insulin during pregnancy." | 3.70 | Oral hypoglycaemic agents in 118 diabetic pregnancies. ( Damm, P; Hellmuth, E; Mølsted-Pedersen, L, 2000) |
| "Metformin has a molecular weight of 129 Daltons and therefore readily crosses the placenta." | 2.55 | Metformin, the aspirin of the 21st century: its role in gestational diabetes mellitus, prevention of preeclampsia and cancer, and the promotion of longevity. ( Conde-Agudelo, A; Erez, O; Grossman, LI; Hüttemann, M; Maymon, E; Pacora, P; Panaitescu, B; Romero, R; Yoon, BH, 2017) |
| "Metformin may be beneficial in treating gestational diabetes." | 2.53 | Metformin versus insulin in gestational diabetes mellitus: a meta-analysis of randomized clinical trials. ( Cao, YS; Fan, YY; Li, XG; Liu, T; Wang, L; Zhang, L; Zhao, ZG; Zhu, B, 2016) |
| "Maternal obesity is associated with adverse perinatal outcome." | 2.52 | Placental dysfunction in obese women and antenatal surveillance strategies. ( Doshani, A; Jeve, YB; Konje, JC, 2015) |
| "Studies of the use of metformin in gestational diabetes show at least equivalent neonatal outcomes, while reporting reductions in neonatal hypoglycaemia, maternal hypoglycaemia and weight gain and improved treatment satisfaction." | 2.50 | The use of oral hypoglycaemic agents in pregnancy. ( Holt, RI; Lambert, KD, 2014) |
| "To assess whether coexisting fetal growth restriction (FGR) influences pregnancy latency among women with preterm pre-eclampsia undergoing expectant management." | 1.91 | Impact of fetal growth restriction on pregnancy outcome in women undergoing expectant management for preterm pre-eclampsia. ( Bergkvist, J; Bergman, L; Cluver, CA; Geerts, L; Hall, DR; Imberg, H; Mol, BW; Tong, S; Walker, SP, 2023) |
| "Fetal growth restriction is a leading cause of stillbirth that often remains undetected during pregnancy." | 1.62 | Circulating syndecan-1 is reduced in pregnancies with poor fetal growth and its secretion regulated by matrix metalloproteinases and the mitochondria. ( Brownfoot, F; Cannon, P; Cruickshank, T; Garcha, D; Hannan, NJ; Hyett, J; Illanes, SE; Jellins, J; Kaitu'u-Lino, TJ; Kandel, M; Keenan, E; MacDonald, TM; Masci, J; Middleton, A; Murphy, C; Murray, E; Myers, J; Nguyen, TV; Nien, JK; Pell, G; Pritchard, N; Roddy Mitchell, A; Schepeler, M; Tong, S; Walker, SP; Whigham, CA; Wong, GP, 2021) |
| "Metformin (Met) has been found to modify the methylation of H19 and to alter its expression." | 1.51 | Metformin exhibits its therapeutic effect in the treatment of pre-eclampsia via modulating the Met/H19/miR-148a-5p/P28 and Met/H19/miR-216-3p/EBI3 signaling pathways. ( Chen, C; Dong, S; Gu, J; He, J; Mo, Y; Shah, NK; Shu, C; Wu, L; Yan, D, 2019) |
| "Metformin has potential to prevent or treat preeclampsia." | 1.43 | Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction. ( Brownfoot, FC; Cannon, P; Hannan, NJ; Hastie, R; Illanes, SE; Kaitu'u-Lino, TJ; Parry, LJ; Senadheera, S; Tong, S; Tuohey, L, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (10.00) | 29.6817 |
| 2010's | 24 (60.00) | 24.3611 |
| 2020's | 12 (30.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cluver, CA | 2 |
| Hiscock, R | 2 |
| Decloedt, EH | 1 |
| Hall, DR | 2 |
| Schell, S | 1 |
| Mol, BW | 3 |
| Brownfoot, F | 3 |
| Kaitu'u-Lino, TJ | 7 |
| Walker, SP | 4 |
| Tong, S | 9 |
| Fornes, R | 1 |
| Simin, J | 1 |
| Nguyen, MH | 1 |
| Cruz, G | 1 |
| Crisosto, N | 1 |
| van der Schaaf, M | 1 |
| Engstrand, L | 1 |
| Brusselaers, N | 1 |
| McDougall, ARA | 1 |
| Hastie, R | 5 |
| Goldstein, M | 1 |
| Tuttle, A | 1 |
| Ammerdorffer, A | 1 |
| Gülmezoglu, AM | 1 |
| Vogel, JP | 1 |
| Bergman, L | 1 |
| Bergkvist, J | 1 |
| Imberg, H | 1 |
| Geerts, L | 1 |
| He, L | 1 |
| Wu, X | 1 |
| Zhan, F | 1 |
| Li, X | 1 |
| Wu, J | 1 |
| Ujvari, D | 1 |
| Trouva, A | 1 |
| Hirschberg, AL | 1 |
| Vanky, E | 2 |
| Ding, Y | 1 |
| Yuan, X | 1 |
| Gu, W | 1 |
| Lu, L | 1 |
| Wang, F | 1 |
| Cao, G | 1 |
| Yi, W | 1 |
| Li, L | 2 |
| Cao, X | 1 |
| Brownfoot, FC | 4 |
| Hannan, NJ | 4 |
| Cannon, P | 4 |
| Nguyen, TV | 3 |
| Tuohey, L | 2 |
| Cluver, C | 3 |
| Virtanen, A | 1 |
| Huttala, O | 1 |
| Tihtonen, K | 1 |
| Toimela, T | 1 |
| Heinonen, T | 1 |
| Laivuori, H | 1 |
| Uotila, J | 1 |
| Hannan, N | 1 |
| Aye, ILMH | 1 |
| Aiken, CE | 1 |
| Charnock-Jones, DS | 1 |
| Smith, GCS | 1 |
| Racine, JL | 1 |
| Adams, JH | 1 |
| Antony, KM | 1 |
| Hoppe, KK | 1 |
| Iruretagoyena, JI | 1 |
| Stewart, KS | 1 |
| Eddy, A | 1 |
| Rhoades, JS | 1 |
| Garcha, D | 1 |
| MacDonald, TM | 1 |
| Hyett, J | 1 |
| Jellins, J | 1 |
| Myers, J | 1 |
| Illanes, SE | 2 |
| Nien, JK | 1 |
| Schepeler, M | 1 |
| Keenan, E | 1 |
| Whigham, CA | 1 |
| Murray, E | 1 |
| Kandel, M | 1 |
| Masci, J | 1 |
| Murphy, C | 1 |
| Cruickshank, T | 1 |
| Pritchard, N | 1 |
| Roddy Mitchell, A | 1 |
| Middleton, A | 1 |
| Pell, G | 1 |
| Wong, GP | 1 |
| Romero, R | 1 |
| Erez, O | 1 |
| Hüttemann, M | 1 |
| Maymon, E | 1 |
| Panaitescu, B | 1 |
| Conde-Agudelo, A | 1 |
| Pacora, P | 1 |
| Yoon, BH | 1 |
| Grossman, LI | 1 |
| Alqudah, A | 1 |
| McKinley, MC | 1 |
| McNally, R | 1 |
| Graham, U | 1 |
| Watson, CJ | 1 |
| Lyons, TJ | 1 |
| McClements, L | 1 |
| Beard, S | 1 |
| Binder, NK | 1 |
| Kalafat, E | 1 |
| Sukur, YE | 1 |
| Abdi, A | 1 |
| Thilaganathan, B | 1 |
| Khalil, A | 1 |
| Feig, D | 1 |
| Nascimento, IBD | 1 |
| Dienstmann, G | 1 |
| de Souza, MLR | 1 |
| Fleig, R | 1 |
| Hoffmann, CBPC | 1 |
| Silva, JC | 1 |
| Kocan, M | 1 |
| Duran, I | 1 |
| Entler, S | 1 |
| Vayakis, G | 1 |
| Agostinetti, P | 1 |
| Brombin, M | 1 |
| Carmona, JM | 1 |
| Gambetta, G | 1 |
| Jirman, T | 1 |
| Marconato, N | 1 |
| Moreau, P | 1 |
| Peruzzo, S | 1 |
| Spuig, P | 1 |
| Walsh, M | 1 |
| Bashir, M | 1 |
| Dabbous, Z | 1 |
| Baagar, K | 1 |
| Elkhatib, F | 1 |
| Ibrahim, A | 1 |
| Brich, SA | 1 |
| Abdel-Rahman, ME | 1 |
| Konje, JC | 2 |
| Abou-Samra, AB | 1 |
| Hall, D | 1 |
| Shu, C | 1 |
| Yan, D | 1 |
| Chen, C | 1 |
| Mo, Y | 1 |
| Wu, L | 1 |
| Gu, J | 1 |
| Shah, NK | 1 |
| He, J | 1 |
| Dong, S | 1 |
| Hu, J | 1 |
| Zhang, J | 1 |
| Zhu, B | 2 |
| Holt, RI | 1 |
| Lambert, KD | 1 |
| Han, CS | 1 |
| Herrin, MA | 1 |
| Pitruzzello, MC | 1 |
| Mulla, MJ | 1 |
| Werner, EF | 1 |
| Pettker, CM | 1 |
| Flannery, CA | 1 |
| Abrahams, VM | 1 |
| Jeve, YB | 1 |
| Doshani, A | 1 |
| Ainuddin, J | 1 |
| Karim, N | 1 |
| Hasan, AA | 1 |
| Naqvi, SA | 1 |
| Li, G | 1 |
| Zhao, S | 1 |
| Cui, S | 1 |
| Xu, Y | 1 |
| Li, Y | 1 |
| Feng, L | 1 |
| Lin, XF | 1 |
| Wan, ZH | 1 |
| Hu, D | 1 |
| Du, YK | 1 |
| Parry, LJ | 1 |
| Senadheera, S | 1 |
| Zhang, L | 1 |
| Fan, YY | 1 |
| Wang, L | 1 |
| Li, XG | 1 |
| Liu, T | 1 |
| Cao, YS | 1 |
| Zhao, ZG | 1 |
| Tan, X | 1 |
| Li, S | 1 |
| Chang, Y | 1 |
| Fang, C | 1 |
| Liu, H | 1 |
| Zhang, X | 1 |
| Wang, Y | 1 |
| Stridsklev, S | 1 |
| Heimstad, R | 1 |
| Romundstad, P | 1 |
| Skogøy, K | 1 |
| Kleggetveit, O | 1 |
| Hjelle, S | 1 |
| von Brandis, P | 1 |
| Eikeland, T | 1 |
| Flo, K | 1 |
| Berg, KF | 1 |
| Bunford, G | 1 |
| Lund, A | 1 |
| Bjerke, C | 1 |
| Almås, I | 1 |
| Berg, AH | 1 |
| Danielson, A | 1 |
| Lahmami, G | 1 |
| Carlsen, SM | 1 |
| Khattab, S | 1 |
| Mohsen, IA | 1 |
| Aboul Foutouh, I | 1 |
| Ashmawi, HS | 1 |
| Mohsen, MN | 1 |
| van Wely, M | 1 |
| van der Veen, F | 1 |
| Youssef, MA | 1 |
| Glueck, CJ | 3 |
| Goldenberg, N | 3 |
| Pranikoff, J | 3 |
| Khan, Z | 1 |
| Padda, J | 1 |
| Wang, P | 3 |
| Loftspring, M | 1 |
| Sieve, L | 1 |
| Bornovali, S | 1 |
| Dharashivkar, S | 1 |
| Hughes, RC | 1 |
| Rowan, JA | 1 |
| Hellmuth, E | 1 |
| Damm, P | 1 |
| Mølsted-Pedersen, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Preeclampsia Intervention 4 - A Triple Blind Phase III Randomised Controlled Trial Assessing Metformin to Prolong Gestation in Preterm Preeclampsia[NCT06033131] | Phase 3 | 294 participants (Anticipated) | Interventional | 2024-01-22 | Not yet recruiting | ||
| Prevention of Pre-eclampsia Using Metformin: a Randomized Control Trial[NCT04855513] | 414 participants (Anticipated) | Interventional | 2022-03-24 | Not yet recruiting | |||
| Non-inferiority Between Acarbose and Prandial Insulin for the Treatment of Gestational Diabetes Mellitus: a Randomized Multicenter and Prospective Trial. ACARB-GDM Study.[NCT03380546] | Phase 3 | 341 participants (Actual) | Interventional | 2018-07-04 | Active, not recruiting | ||
| Aspirin Versus Metformin in Pregnancies at High Risk of Preterm Preeclampsia: a 3-arm Randomized Controlled Trial[NCT05580523] | 3,000 participants (Anticipated) | Interventional | 2023-07-03 | Recruiting | |||
| A Multi-center, Prospective, Cohort Study to Elucidate the Effects of Metformin Treatment on Steroid Hormones and Social Behavior. Linking Autistic Behaviorial Symptoms to Changes in Steroid Hormone Availability[NCT04930471] | 45 participants (Anticipated) | Observational | 2021-06-30 | Not yet recruiting | |||
| Metformin Treatment of Pregnant Women With Polycystic Ovary Syndrome (PCOS)[NCT00159536] | Phase 3 | 257 participants (Actual) | Interventional | 2005-02-28 | Completed | ||
| Effect of Metformin on Healthy Live Birth After In-vitro Fertilization in Women With Prediabetes Mellitus: a Multicenter Double-blind Placebo Controlled Randomized Trial[NCT06064669] | 988 participants (Anticipated) | Interventional | 2023-10-01 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
13 reviews available for metformin and Pre-Eclampsia
| Article | Year |
|---|---|
Pravastatin, proton-pump inhibitors, metformin, micronutrients, and biologics: new horizons for the prevention or treatment of preeclampsia.
Topics: Antibodies, Monoclonal; Antioxidants; Antithrombin III; Biological Products; Blood Component Removal | 2022 |
Placental energy metabolism in health and disease-significance of development and implications for preeclampsia.
Topics: Antioxidants; Energy Metabolism; Epigenesis, Genetic; Female; Gene Expression; Homeostasis; Humans; | 2022 |
Metformin, the aspirin of the 21st century: its role in gestational diabetes mellitus, prevention of preeclampsia and cancer, and the promotion of longevity.
Topics: Diabetes, Gestational; Female; Fetal Development; Humans; Hypoglycemic Agents; Longevity; Maternal N | 2017 |
Risk of pre-eclampsia in women taking metformin: a systematic review and meta-analysis.
Topics: Adult; Cohort Studies; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Hypoglycemi | 2018 |
Metformin for prevention of hypertensive disorders of pregnancy in women with gestational diabetes or obesity: systematic review and meta-analysis of randomized trials.
Topics: Bayes Theorem; Diabetes, Gestational; Female; Glyburide; Humans; Hypertension, Pregnancy-Induced; In | 2018 |
Meta-analysis suggests that metformin may reduce pre-eclampsia compared with insulin use during pregnancy.
Topics: Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Insulins; Metformin; Pre-Eclampsia; Preg | 2019 |
Topics: Clinical Trials as Topic; Female; Humans; Metformin; Pre-Eclampsia; Pregnancy; Treatment Outcome | 2018 |
The use of oral hypoglycaemic agents in pregnancy.
Topics: Birth Weight; Blood Glucose; Diabetes, Gestational; Female; Glycoside Hydrolase Inhibitors; Humans; | 2014 |
Placental dysfunction in obese women and antenatal surveillance strategies.
Topics: Diabetes, Gestational; Female; Fetal Development; Humans; Hypoglycemic Agents; Inflammation; Metform | 2015 |
Effect comparison of metformin with insulin treatment for gestational diabetes: a meta-analysis based on RCTs.
Topics: Birth Weight; Diabetes, Gestational; Female; Gestational Age; Humans; Insulin; Metformin; Pre-Eclamp | 2015 |
Efficacy of metformin on pregnancy complications in women with polycystic ovary syndrome: a meta-analysis.
Topics: Abortion, Spontaneous; Case-Control Studies; Diabetes, Gestational; Female; Humans; Hypoglycemic Age | 2015 |
Metformin versus insulin in gestational diabetes mellitus: a meta-analysis of randomized clinical trials.
Topics: Birth Weight; Cesarean Section; Diabetes, Gestational; Female; Gestational Age; Humans; Infant, Newb | 2016 |
Effect of metformin treatment during pregnancy on women with PCOS: a systematic review and meta-analysis.
Topics: Abortion, Spontaneous; Birth Weight; Diabetes, Gestational; Evidence-Based Medicine; Female; Humans; | 2016 |
Effect of metformin treatment during pregnancy on women with PCOS: a systematic review and meta-analysis.
Topics: Abortion, Spontaneous; Birth Weight; Diabetes, Gestational; Evidence-Based Medicine; Female; Humans; | 2016 |
Effect of metformin treatment during pregnancy on women with PCOS: a systematic review and meta-analysis.
Topics: Abortion, Spontaneous; Birth Weight; Diabetes, Gestational; Evidence-Based Medicine; Female; Humans; | 2016 |
Effect of metformin treatment during pregnancy on women with PCOS: a systematic review and meta-analysis.
Topics: Abortion, Spontaneous; Birth Weight; Diabetes, Gestational; Evidence-Based Medicine; Female; Humans; | 2016 |
6 trials available for metformin and Pre-Eclampsia
| Article | Year |
|---|---|
Use of metformin to prolong gestation in preterm pre-eclampsia: randomised, double blind, placebo controlled trial.
Topics: Adult; Delayed-Action Preparations; Double-Blind Method; Endoglin; Female; Gestational Age; Humans; | 2021 |
Maternal serum levels of prokineticin-1 related to pregnancy complications and metformin use in women with polycystic ovary syndrome: a post hoc analysis of two prospective, randomised, placebo-controlled trials.
Topics: Female; Gastrointestinal Hormones; Humans; Hyperandrogenism; Hypoglycemic Agents; Infant, Newborn; M | 2023 |
Metformin versus insulin treatment in gestational diabetes in pregnancy in a developing country: a randomized control trial.
Topics: Adult; Blood Glucose; Developing Countries; Diabetes, Gestational; Drug Therapy, Combination; Female | 2015 |
Metformin versus placebo from first trimester to delivery in polycystic ovary syndrome: a randomized, controlled multicenter study.
Topics: Adult; Blood Pressure; Delivery, Obstetric; Diabetes, Gestational; Double-Blind Method; Female; Hear | 2010 |
Effects of metformin-diet intervention before and throughout pregnancy on obstetric and neonatal outcomes in patients with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Adult; Diabetes, Gestational; Female; Fetal Macrosomia; Humans; Hypoglycemic | 2013 |
Height, weight, and motor-social development during the first 18 months of life in 126 infants born to 109 mothers with polycystic ovary syndrome who conceived on and continued metformin through pregnancy.
Topics: Adult; Body Height; Body Weight; Child Development; Diabetes, Gestational; Female; Humans; Hypoglyce | 2004 |
21 other studies available for metformin and Pre-Eclampsia
| Article | Year |
|---|---|
Pregnancy, perinatal and childhood outcomes in women with and without polycystic ovary syndrome and metformin during pregnancy: a nationwide population-based study.
Topics: Adult; Child; Child, Preschool; Cohort Studies; Diabetes, Gestational; Female; Humans; Infant, Newbo | 2022 |
Systematic evaluation of the pre-eclampsia drugs, dietary supplements and biologicals pipeline using target product profiles.
Topics: Biological Products; Dietary Supplements; Female; Humans; Metformin; Pre-Eclampsia; Pregnancy; Vitam | 2022 |
Impact of fetal growth restriction on pregnancy outcome in women undergoing expectant management for preterm pre-eclampsia.
Topics: Cesarean Section; Female; Fetal Growth Retardation; Humans; Infant; Infant, Newborn; Metformin; Pre- | 2023 |
Protective role of metformin in preeclampsia via the regulation of NF-κB/sFlt-1 and Nrf2/HO-1 signaling pathways by activating AMPK.
Topics: AMP-Activated Protein Kinases; Female; Humans; Inflammation; Lipopolysaccharides; Metformin; NF-E2-R | 2023 |
Treatment with metformin prevents pre-eclampsia by suppressing migration of trophoblast cells via modulating the signaling pathway of UCA1/miR-204/MMP-9.
Topics: Cell Movement; Computer Simulation; Female; Human Umbilical Vein Endothelial Cells; Humans; Matrix M | 2019 |
Effect of Metformin on a Preeclampsia-Like Mouse Model Induced by High-Fat Diet.
Topics: Animals; Blood Pressure; Body Weight; Diet, High-Fat; Disease Models, Animal; Female; Matrix Metallo | 2019 |
Combining metformin and sulfasalazine additively reduces the secretion of antiangiogenic factors from the placenta: Implications for the treatment of preeclampsia.
Topics: Drug Therapy, Combination; Endoglin; Endothelin-1; Female; Humans; Metformin; Placenta; Placenta Gro | 2020 |
Therapeutic doses of metformin do not have impact on angiogenesis in presence of sera from pre-eclamptic, IUGR and healthy pregnancies.
Topics: Adult; Angiogenesis Inhibitors; Case-Control Studies; Dose-Response Relationship, Drug; Female; Feta | 2020 |
Metformin Exposure and Risk of Hypertensive Disorders of Pregnancy in Patients with Type 2 Diabetes.
Topics: Adult; Birth Weight; Diabetes Mellitus, Type 2; Female; Fetal Growth Retardation; Humans; Hypertensi | 2021 |
Circulating syndecan-1 is reduced in pregnancies with poor fetal growth and its secretion regulated by matrix metalloproteinases and the mitochondria.
Topics: Adult; Area Under Curve; Birth Weight; Cell Hypoxia; Delivery, Obstetric; Diabetes, Gestational; Ele | 2021 |
Combining metformin and esomeprazole is additive in reducing sFlt-1 secretion and decreasing endothelial dysfunction - implications for treating preeclampsia.
Topics: Endothelium, Vascular; Esomeprazole; Female; Human Umbilical Vein Endothelial Cells; Humans; Metform | 2018 |
Type 2 diabetes mellitus in pregnancy: The impact of maternal weight and early glycaemic control on outcomes.
Topics: Adult; Case-Control Studies; Cesarean Section; Diabetes Mellitus, Type 2; Female; Fetal Macrosomia; | 2019 |
A double blind, randomised, placebo-controlled trial to evaluate the efficacy of metformin to treat preterm pre-eclampsia (PI2 Trial): study protocol.
Topics: Double-Blind Method; Female; Humans; Metformin; Placebos; Pre-Eclampsia; Pregnancy; Randomized Contr | 2019 |
Metformin exhibits its therapeutic effect in the treatment of pre-eclampsia via modulating the Met/H19/miR-148a-5p/P28 and Met/H19/miR-216-3p/EBI3 signaling pathways.
Topics: Animals; Cells, Cultured; DNA Methylation; Female; Gene Expression Regulation; Interleukin-6; Interl | 2019 |
Protective effect of metformin on a rat model of lipopolysaccharide-induced preeclampsia.
Topics: Animals; Disease Models, Animal; Female; Lipopolysaccharides; Metformin; NF-kappa B; Oxidative Stres | 2019 |
Glucose and metformin modulate human first trimester trophoblast function: a model and potential therapy for diabetes-associated uteroplacental insufficiency.
Topics: Angiogenesis Inducing Agents; Antigens, CD; Carrier Proteins; Cell Line; Cell Movement; Chemokine CC | 2015 |
Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction.
Topics: Antigens, CD; Biomarkers; Cardiovascular Agents; Electron Transport Chain Complex Proteins; Endoglin | 2016 |
Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction.
Topics: Antigens, CD; Biomarkers; Cardiovascular Agents; Electron Transport Chain Complex Proteins; Endoglin | 2016 |
Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction.
Topics: Antigens, CD; Biomarkers; Cardiovascular Agents; Electron Transport Chain Complex Proteins; Endoglin | 2016 |
Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction.
Topics: Antigens, CD; Biomarkers; Cardiovascular Agents; Electron Transport Chain Complex Proteins; Endoglin | 2016 |
Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction.
Topics: Antigens, CD; Biomarkers; Cardiovascular Agents; Electron Transport Chain Complex Proteins; Endoglin | 2016 |
Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction.
Topics: Antigens, CD; Biomarkers; Cardiovascular Agents; Electron Transport Chain Complex Proteins; Endoglin | 2016 |
Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction.
Topics: Antigens, CD; Biomarkers; Cardiovascular Agents; Electron Transport Chain Complex Proteins; Endoglin | 2016 |
Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction.
Topics: Antigens, CD; Biomarkers; Cardiovascular Agents; Electron Transport Chain Complex Proteins; Endoglin | 2016 |
Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction.
Topics: Antigens, CD; Biomarkers; Cardiovascular Agents; Electron Transport Chain Complex Proteins; Endoglin | 2016 |
Can metformin reduce the incidence of gestational diabetes mellitus in pregnant women with polycystic ovary syndrome? Prospective cohort study.
Topics: Abdominal Pain; Adult; Cohort Studies; Diabetes, Gestational; Egypt; Female; Fertilization in Vitro; | 2011 |
Metformin, pre-eclampsia, and pregnancy outcomes in women with polycystic ovary syndrome.
Topics: Adult; Birth Weight; Body Weight; Diabetes, Gestational; Female; Gestational Age; HELLP Syndrome; Hu | 2004 |
Pregnancy in women with Type 2 diabetes: who takes metformin and what is the outcome?
Topics: Adult; Body Mass Index; Chronic Disease; Delivery, Obstetric; Diabetes Mellitus, Type 2; Female; Fet | 2006 |
Oral hypoglycaemic agents in 118 diabetic pregnancies.
Topics: Abruptio Placentae; Adult; Birth Weight; Cesarean Section; Cohort Studies; Diabetes Mellitus, Type 2 | 2000 |